ENSG00000102974 |
|
HER2 Positive Breast Carcinoma |
sequence_alteration |
9.649% (11/114) |
1 entry |
ENSG00000102974 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
19.76% (261/1321) |
4 entries |
ENSG00000102974 |
|
colorectal adenocarcinoma |
sequence_alteration |
5.308% (62/1168) |
2 entries |
ENSG00000102974 |
|
colorectal adenocarcinoma |
stop_gained |
5.308% (62/1168) |
2 entries |
ENSG00000102974 |
|
colorectal adenocarcinoma |
frameshift_variant |
5.308% (62/1168) |
2 entries |
ENSG00000102974 |
|
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
19.76% (261/1321) |
4 entries |
ENSG00000102974 |
|
colorectal adenocarcinoma |
missense_variant |
5.308% (62/1168) |
2 entries |
ENSG00000102974 |
|
Endometrial Endometrioid Adenocarcinoma |
frameshift_variant |
19.76% (261/1321) |
5 entries |
ENSG00000102974 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
19.76% (261/1321) |
4 entries |
ENSG00000102974 |
|
lung adenocarcinoma |
missense_variant |
0.9062% (23/2538) |
2 entries |
ENSG00000102974 |
|
lung adenocarcinoma |
sequence_alteration |
0.9062% (23/2538) |
3 entries |
ENSG00000102974 |
|
acute lymphoblastic leukemia |
frameshift_variant |
2.491% (14/562) |
1 entry |
ENSG00000102974 |
|
breast phyllodes tumor |
sequence_alteration |
2.778% (3/108) |
1 entry |
ENSG00000102974 |
|
breast carcinoma |
sequence_alteration |
1.667% (29/1740) |
7 entries |
ENSG00000102974 |
|
Breast Carcinoma by Gene Expression Profile |
frameshift_variant |
2.224% (28/1259) |
1 entry |
ENSG00000102974 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_lost |
19.76% (261/1321) |
1 entry |
ENSG00000102974 |
|
gastric adenocarcinoma |
missense_variant |
1.667% (12/720) |
1 entry |
ENSG00000102974 |
|
bladder transitional cell carcinoma |
sequence_alteration |
2.165% (10/462) |
1 entry |
ENSG00000102974 |
|
pancreatic ductal adenocarcinoma |
sequence_alteration |
2.422% (41/1693) |
2 entries |
ENSG00000102974 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.6472% (6/927) |
4 entries |
ENSG00000102974 |
|
prostate carcinoma |
sequence_alteration |
2.575% (12/466) |
2 entries |
ENSG00000102974 |
|
Breast Carcinoma by Gene Expression Profile |
sequence_alteration |
2.224% (28/1259) |
3 entries |
ENSG00000102974 |
|
breast carcinoma |
frameshift_variant |
1.667% (29/1740) |
2 entries |
ENSG00000102974 |
|
bladder transitional cell carcinoma |
frameshift_variant |
2.165% (10/462) |
2 entries |
ENSG00000102974 |
|
melanoma |
missense_variant |
2.069% (3/145) |
3 entries |
ENSG00000102974 |
|
basal cell carcinoma |
missense_variant |
2.941% (2/68) |
1 entry |
ENSG00000102974 |
|
acute lymphoblastic leukemia |
stop_gained |
2.491% (14/562) |
1 entry |
ENSG00000102974 |
|
brain glioblastoma |
sequence_alteration |
0.495% (6/1212) |
2 entries |
ENSG00000102974 |
|
cecum adenocarcinoma |
missense_variant |
4.545% (12/264) |
1 entry |
ENSG00000102974 |
|
urothelial carcinoma |
sequence_alteration |
9.302% (8/86) |
1 entry |
ENSG00000102974 |
|
bladder transitional cell carcinoma |
missense_variant |
2.165% (10/462) |
2 entries |
ENSG00000102974 |
|
cecum adenocarcinoma |
stop_gained |
4.545% (12/264) |
2 entries |
ENSG00000102974 |
|
urothelial carcinoma |
stop_gained |
9.302% (8/86) |
1 entry |
ENSG00000102974 |
|
skin melanoma |
missense_variant |
0.5164% (6/1162) |
1 entry |
ENSG00000102974 |
|
breast phyllodes tumor |
frameshift_variant |
2.778% (3/108) |
1 entry |
ENSG00000102974 |
|
Ovarian Endometriosis |
missense_variant |
2.174% (2/92) |
1 entry |
ENSG00000102974 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
0.5814% (2/344) |
2 entries |
ENSG00000102974 |
|
prostate adenocarcinoma |
frameshift_variant |
1.668% (36/2158) |
1 entry |
ENSG00000102974 |
|
clear cell renal carcinoma |
sequence_alteration |
0.3411% (5/1466) |
2 entries |
ENSG00000102974 |
|
cecum adenocarcinoma |
sequence_alteration |
4.545% (12/264) |
1 entry |
ENSG00000102974 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
2.422% (41/1693) |
1 entry |
ENSG00000102974 |
|
acute myeloid leukemia |
stop_gained |
1.618% (21/1298) |
2 entries |
ENSG00000102974 |
|
diffuse large B-cell lymphoma |
sequence_alteration |
1.351% (5/370) |
1 entry |
ENSG00000102974 |
|
urothelial carcinoma |
frameshift_variant |
9.302% (8/86) |
1 entry |
ENSG00000102974 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
10.59% (9/85) |
2 entries |
ENSG00000102974 |
|
Breast Carcinoma by Gene Expression Profile |
missense_variant |
2.224% (28/1259) |
3 entries |
ENSG00000102974 |
|
kidney Wilms tumor |
missense_variant |
0.5277% (2/379) |
1 entry |
ENSG00000102974 |
|
diffuse large B-cell lymphoma |
missense_variant |
1.351% (5/370) |
2 entries |
ENSG00000102974 |
|
skin melanoma |
sequence_alteration |
0.5164% (6/1162) |
1 entry |
ENSG00000102974 |
|
breast ductal adenocarcinoma |
sequence_alteration |
3.107% (54/1738) |
5 entries |
ENSG00000102974 |
|
ovarian serous adenocarcinoma |
sequence_alteration |
0.6472% (6/927) |
2 entries |
ENSG00000102974 |
|
acute myeloid leukemia |
missense_variant |
1.618% (21/1298) |
3 entries |
ENSG00000102974 |
|
acute lymphoblastic leukemia |
sequence_alteration |
2.491% (14/562) |
1 entry |
ENSG00000102974 |
|
basal cell carcinoma |
sequence_alteration |
2.941% (2/68) |
1 entry |
ENSG00000102974 |
|
hepatocellular carcinoma |
missense_variant |
1.22% (12/984) |
3 entries |
ENSG00000102974 |
|
breast ductal adenocarcinoma |
missense_variant |
3.107% (54/1738) |
2 entries |
ENSG00000102974 |
|
bladder carcinoma |
missense_variant |
2.317% (13/561) |
1 entry |
ENSG00000102974 |
|
T-cell acute lymphoblastic leukemia |
sequence_alteration |
3.409% (27/792) |
3 entries |
ENSG00000102974 |
|
gastric intestinal type adenocarcinoma |
frameshift_variant |
10.59% (9/85) |
2 entries |
ENSG00000102974 |
|
T-cell acute lymphoblastic leukemia |
missense_variant |
3.409% (27/792) |
2 entries |
ENSG00000102974 |
|
Uterine Carcinosarcoma |
sequence_alteration |
2.027% (3/148) |
1 entry |
ENSG00000102974 |
|
colon adenocarcinoma |
frameshift_variant |
2.617% (33/1261) |
3 entries |
ENSG00000102974 |
|
colon adenocarcinoma |
stop_gained |
2.617% (33/1261) |
2 entries |
ENSG00000102974 |
|
hepatocellular carcinoma |
sequence_alteration |
1.22% (12/984) |
2 entries |
ENSG00000102974 |
|
Breast Carcinoma by Gene Expression Profile |
stop_gained |
2.224% (28/1259) |
1 entry |
ENSG00000102974 |
|
T-cell acute lymphoblastic leukemia |
stop_gained |
3.409% (27/792) |
3 entries |
ENSG00000102974 |
|
HER2 Positive Breast Carcinoma |
stop_gained |
9.649% (11/114) |
1 entry |
ENSG00000102974 |
|
gastric adenocarcinoma |
frameshift_variant |
1.667% (12/720) |
1 entry |
ENSG00000102974 |
|
gastric intestinal type adenocarcinoma |
sequence_alteration |
10.59% (9/85) |
2 entries |
ENSG00000102974 |
|
small cell lung carcinoma |
sequence_alteration |
0.6818% (3/440) |
2 entries |
ENSG00000102974 |
|
colon adenocarcinoma |
sequence_alteration |
2.617% (33/1261) |
3 entries |
ENSG00000102974 |
|
rectal adenocarcinoma |
frameshift_variant |
1.832% (10/546) |
1 entry |
ENSG00000102974 |
|
Merkel cell skin cancer |
sequence_alteration |
3.191% (3/94) |
2 entries |
ENSG00000102974 |
|
female breast carcinoma |
sequence_alteration |
2.74% (8/292) |
3 entries |
ENSG00000102974 |
|
Invasive Breast Carcinoma |
sequence_alteration |
4.444% (2/45) |
1 entry |
ENSG00000102974 |
|
cecum adenocarcinoma |
frameshift_variant |
4.545% (12/264) |
1 entry |
ENSG00000102974 |
|
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
0.6696% (3/448) |
1 entry |
ENSG00000102974 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.974% (3/308) |
1 entry |
ENSG00000102974 |
|
pancreatic neuroendocrine tumor |
missense_variant |
2.542% (6/236) |
1 entry |
ENSG00000102974 |
|
rectal adenocarcinoma |
missense_variant |
1.832% (10/546) |
2 entries |
ENSG00000102974 |
|
chronic myelomonocytic leukemia |
missense_variant |
2.41% (2/83) |
1 entry |
ENSG00000102974 |
|
breast ductal adenocarcinoma |
frameshift_variant |
3.107% (54/1738) |
4 entries |
ENSG00000102974 |
|
small cell lung carcinoma |
missense_variant |
0.6818% (3/440) |
2 entries |
ENSG00000102974 |
|
acute myeloid leukemia |
sequence_alteration |
1.618% (21/1298) |
3 entries |
ENSG00000102974 |
|
breast carcinoma |
missense_variant |
1.667% (29/1740) |
5 entries |
ENSG00000102974 |
|
colon adenocarcinoma |
missense_variant |
2.617% (33/1261) |
4 entries |
ENSG00000102974 |
|
small intestinal adenocarcinoma |
frameshift_variant |
19.05% (4/21) |
1 entry |
ENSG00000102974 |
|
T-cell acute lymphoblastic leukemia |
frameshift_variant |
3.409% (27/792) |
3 entries |
ENSG00000102974 |
|
lung adenocarcinoma |
stop_gained |
0.9062% (23/2538) |
2 entries |
ENSG00000102974 |
|
gastric adenocarcinoma |
sequence_alteration |
1.667% (12/720) |
1 entry |
ENSG00000102974 |
|
brain glioblastoma |
missense_variant |
0.495% (6/1212) |
2 entries |
ENSG00000102974 |
|
prostate adenocarcinoma |
missense_variant |
1.668% (36/2158) |
1 entry |
ENSG00000102974 |
|
urothelial carcinoma |
missense_variant |
9.302% (8/86) |
1 entry |
ENSG00000102974 |
|
acute lymphoblastic leukemia |
missense_variant |
2.491% (14/562) |
3 entries |
ENSG00000102974 |
|
prostate carcinoma |
missense_variant |
2.575% (12/466) |
2 entries |
ENSG00000102974 |
|
female breast carcinoma |
missense_variant |
2.74% (8/292) |
3 entries |
ENSG00000102974 |
|
acute myeloid leukemia |
frameshift_variant |
1.618% (21/1298) |
3 entries |
ENSG00000102974 |
|
rectal adenocarcinoma |
sequence_alteration |
1.832% (10/546) |
3 entries |
ENSG00000102974 |
|
prostate adenocarcinoma |
sequence_alteration |
1.668% (36/2158) |
2 entries |
ENSG00000102974 |
|
chronic lymphocytic leukemia |
sequence_alteration |
0.4489% (4/891) |
1 entry |
ENSG00000102974 |
|
small intestinal adenocarcinoma |
sequence_alteration |
19.05% (4/21) |
1 entry |
ENSG00000102974 |
|
melanoma |
sequence_alteration |
2.069% (3/145) |
2 entries |
ENSG00000102974 |
|
Merkel cell skin cancer |
missense_variant |
3.191% (3/94) |
1 entry |
ENSG00000102974 |
|
Signet Ring Cell Gastric Adenocarcinoma |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000102974 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
sequence_alteration |
0.3788% (1/264) |
1 entry |
ENSG00000102974 |
|
medulloblastoma |
missense_variant |
4.167% (1/24) |
1 entry |
ENSG00000102974 |
|
laryngeal squamous cell carcinoma |
missense_variant |
2.439% (1/41) |
1 entry |
ENSG00000102974 |
|
gastric tubular adenocarcinoma |
frameshift_variant |
50.0% (1/2) |
1 entry |
ENSG00000102974 |
|
myeloproliferative disorder |
stop_gained |
2.439% (1/41) |
1 entry |
ENSG00000102974 |
|
anaplastic oligodendroglioma |
missense_variant |
1.163% (1/86) |
1 entry |
ENSG00000102974 |
|
esophageal squamous cell carcinoma |
stop_gained |
0.2924% (2/684) |
1 entry |
ENSG00000102974 |
|
endometrial carcinoma |
stop_gained |
2.899% (2/69) |
1 entry |
ENSG00000102974 |
|
metaplastic breast carcinoma |
frameshift_variant |
1.613% (1/62) |
1 entry |
ENSG00000102974 |
|
leiomyosarcoma |
sequence_alteration |
0.9901% (1/101) |
1 entry |
ENSG00000102974 |
|
brain glioblastoma |
frameshift_variant |
0.495% (6/1212) |
1 entry |
ENSG00000102974 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000102974 |
|
Gallbladder Adenocarcinoma |
missense_variant |
0.7143% (1/140) |
1 entry |
ENSG00000102974 |
|
Hodgkins lymphoma |
frameshift_variant |
10.0% (1/10) |
1 entry |
ENSG00000102974 |
|
Appendix Adenocarcinoma |
stop_gained |
1.351% (1/74) |
1 entry |
ENSG00000102974 |
|
T-cell acute lymphoblastic leukemia |
amino_acid_insertion |
3.409% (27/792) |
1 entry |
ENSG00000102974 |
|
B-cell neoplasm |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000102974 |
|
Pleural Epithelioid Mesothelioma |
sequence_alteration |
0.5% (1/200) |
1 entry |
ENSG00000102974 |
|
Ovarian Endometriosis |
sequence_alteration |
2.174% (2/92) |
1 entry |
ENSG00000102974 |
|
myelodysplastic syndrome |
missense_variant |
0.6944% (1/144) |
1 entry |
ENSG00000102974 |
|
Bladder Adenocarcinoma |
missense_variant |
14.29% (1/7) |
1 entry |
ENSG00000102974 |
|
breast ductal adenocarcinoma |
stop_gained |
3.107% (54/1738) |
1 entry |
ENSG00000102974 |
|
female breast carcinoma |
frameshift_variant |
2.74% (8/292) |
1 entry |
ENSG00000102974 |
|
Signet Ring Cell Gastric Adenocarcinoma |
frameshift_variant |
33.33% (1/3) |
1 entry |
ENSG00000102974 |
|
hepatocellular carcinoma |
frameshift_variant |
1.22% (12/984) |
1 entry |
ENSG00000102974 |
|
bile duct adenocarcinoma |
missense_variant |
0.2558% (1/391) |
1 entry |
ENSG00000102974 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
stop_gained |
0.3788% (1/264) |
1 entry |
ENSG00000102974 |
|
chronic myelogenous leukemia |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000102974 |
|
Breast Carcinoma by Gene Expression Profile |
conservative_inframe_deletion |
2.224% (28/1259) |
1 entry |
ENSG00000102974 |
|
pancreatic ductal adenocarcinoma |
frameshift_variant |
2.422% (41/1693) |
1 entry |
ENSG00000102974 |
|
Invasive Breast Carcinoma |
conservative_inframe_deletion |
4.444% (2/45) |
1 entry |
ENSG00000102974 |
|
myeloproliferative disorder |
sequence_alteration |
2.439% (1/41) |
1 entry |
ENSG00000102974 |
|
nasopharyngeal squamous cell carcinoma |
frameshift_variant |
0.974% (3/308) |
1 entry |
ENSG00000102974 |
|
Invasive Breast Carcinoma |
missense_variant |
4.444% (2/45) |
1 entry |
ENSG00000102974 |
|
lobular breast carcinoma |
missense_variant |
1.087% (3/276) |
1 entry |
ENSG00000102974 |
|
skin melanoma |
stop_gained |
0.5164% (6/1162) |
1 entry |
ENSG00000102974 |
|
acute lymphoblastic leukemia |
conservative_inframe_deletion |
2.491% (14/562) |
1 entry |
ENSG00000102974 |
|
bladder transitional cell carcinoma |
stop_gained |
2.165% (10/462) |
1 entry |
ENSG00000102974 |
|
gastric tubular adenocarcinoma |
sequence_alteration |
50.0% (1/2) |
1 entry |
ENSG00000102974 |
|
Uterine Carcinosarcoma |
missense_variant |
2.027% (3/148) |
1 entry |
ENSG00000102974 |
|
Endometrial Undifferentiated Carcinoma |
frameshift_variant |
33.33% (1/3) |
1 entry |
ENSG00000102974 |
|
esophageal adenocarcinoma |
missense_variant |
2.555% (14/548) |
1 entry |
ENSG00000102974 |
|
breast phyllodes tumor |
missense_variant |
2.778% (3/108) |
1 entry |
ENSG00000102974 |
|
breast carcinoma |
conservative_inframe_deletion |
1.667% (29/1740) |
1 entry |
ENSG00000102974 |
|
oral squamous cell carcinoma |
missense_variant |
0.3802% (1/263) |
1 entry |
ENSG00000102974 |
|
endometrial carcinoma |
missense_variant |
2.899% (2/69) |
1 entry |
ENSG00000102974 |
|
endometrial carcinoma |
sequence_alteration |
2.899% (2/69) |
1 entry |
ENSG00000102974 |
|
Appendix Adenocarcinoma |
sequence_alteration |
1.351% (1/74) |
1 entry |
ENSG00000102974 |
|
angioimmunoblastic T-cell lymphoma |
missense_variant |
0.9346% (1/107) |
1 entry |
ENSG00000102974 |
|
myelodysplastic syndrome |
sequence_alteration |
0.6944% (1/144) |
1 entry |
ENSG00000102974 |
|
nasal cavity and paranasal sinus carcinoma |
missense_variant |
16.67% (1/6) |
1 entry |
ENSG00000102974 |
|
diffuse large B-cell lymphoma |
stop_gained |
1.351% (5/370) |
1 entry |
ENSG00000102974 |
|
Pleural Epithelioid Mesothelioma |
missense_variant |
0.5% (1/200) |
1 entry |
ENSG00000102974 |
|
Merkel cell skin cancer |
stop_gained |
3.191% (3/94) |
1 entry |
ENSG00000102974 |
|
salivary gland adenoid cystic carcinoma |
missense_variant |
1.587% (1/63) |
1 entry |
ENSG00000102974 |
|
leiomyosarcoma |
frameshift_variant |
0.9901% (1/101) |
1 entry |
ENSG00000102974 |
|
Hidradenocarcinoma |
missense_variant |
50.0% (1/2) |
1 entry |